Geron Corporation (NASDAQ:GERN) Q4 2022 Earnings Call Transcript

Olivia Bloom: So, Gil thanks. So, it is about a $60 million increase from the €˜22 guidance to where we are in €˜23. And that is driven by a number of categories. So, first, it would be headcount and that’s about 40% of the increase, regulatory submission work and everything that goes along with that for both the U.S. and the EU, that’s another 10%. Commercial manufacturing and building up the inventory of imetelstat, getting ready for potential commercial launch, that’s another 20%. And then in general, other activities related to commercial readiness, which is another 30%. So, I do want to let you know though, that overall, the clinical costs though, still are being maintained in the company because, obviously, we have another Phase 3 trial going on, IMpactMF, as well as the other studies that Faye mentioned.

Gil Blum: Great. Thank you for that. I will jump back in the queue.

Operator: This concludes our Q&A for today. I will now turn the call back to Aron Feingold, for closing remarks.

Aron Feingold: Thanks so much everyone for joining us today. We appreciate you taking the time to listen and participate. We look forward to sharing the achievement of several milestones in the coming year, stay healthy and safe everyone. Bye.

Operator: This concludes today’s conference call. Thank you for attending. You may now disconnect.